Nusinersen (Dutch Wikipedia)

Analysis of information sources in references of the Wikipedia article "Nusinersen" in Dutch language version.

refsWebsite

Global rank Dutch rank

9web.archive.org

1^st place

5doi.org

2^nd place

8^th place

4nih.gov

4^th place

12^th place

2worldcat.org

5^th place

28^th place

1who.int

195^th place

287^th place

1springer.com

274^th place

340^th place

1nytimes.com

7^th place

27^th place

1fda.gov

447^th place

1,002^nd place

1sciencemag.org

857^th place

261^st place

1the-scientist.com

7,827^th place

low place

1wsj.com

79^th place

190^th place

1thepharmaletter.com

low place

1brasil.gov.br

9,094^th place

low place

1sma-schweiz.ch

low place

1dr.dk

1,346^th place

1,662^nd place

1reuters.com

49^th place

102^nd place

1nice.org.uk

3,258^th place

low place

1irishtimes.com

266^th place

914^th place

1treatsma.uk

low place

brasil.gov.br

(pt) Remédio inédito para atrofia muscular espinhal é liberado (25 augustus 2017).

doi.org

(en) Ottesen, Eric W. (1 januari 2017). ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy. Translational Neuroscience 8 (1): 1–6. ISSN: 2081-6936. PMID 28400976. PMC 5382937. DOI: 10.1515/tnsci-2017-0001.
(en) (1 augustus 2018). New warning of nusinersen-related communicating hydrocephalus. Reactions Weekly 1714 (1): 3. ISSN: 1179-2051. DOI: 10.1007/s40278-018-50183-2.
Zanetta, C (1 January 2014). Molecular Therapeutic Strategies for Spinal Muscular Atrophies: Current and Future Clinical Trials. Clinical Therapeutics 36 (1): 128–140. PMID 24360800. DOI: 10.1016/j.clinthera.2013.11.006.
Peng Wen Pao, Keng Boon Wee, Woon Chee Yee and Zacharias Aloysius DwiPramono (April 2014). Dual Masking of Specific Negative Splicing Regulatory Elements Resulted in Maximal Exon 7 Inclusion of SMN2 Gene. Molecular Therapy 22: 854–861. PMID 24317636. PMC 3982506. DOI: 10.1038/mt.2013.276. The sequence of nusinersen (UCACUUUCAUAAUGCUGG) is listed as N1-Hua in Table I.
Garber, K (11 October 2016). Big win possible for Ionis/Biogen antisense drug in muscular atrophy.. Nature Biotechnology 34 (10): 1002–1003. PMID 27727217. DOI: 10.1038/nbt1016-1002.

dr.dk

Medicinrådet siger nej til lægemiddel til børn med muskelsvind: 'Urimeligt' dyrt Retrieved October 13, 2017.

fda.gov

accessdata.fda.gov

Nusinersen US Label. FDA (December 2016). For updates see FDA index page for NDA 209531

irishtimes.com

"Drugmaker urges HSE to revisit pricing of muscle-wasting disease treatment", Irish Times, 25 February 2019. Geraadpleegd op 27 February 2019.

nice.org.uk

Nusinersen for treating spinal muscular atrophy. NICE Technology appraisal guidance [TA588 2019]

nih.gov

ncbi.nlm.nih.gov

(en) Ottesen, Eric W. (1 januari 2017). ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy. Translational Neuroscience 8 (1): 1–6. ISSN: 2081-6936. PMID 28400976. PMC 5382937. DOI: 10.1515/tnsci-2017-0001.
Zanetta, C (1 January 2014). Molecular Therapeutic Strategies for Spinal Muscular Atrophies: Current and Future Clinical Trials. Clinical Therapeutics 36 (1): 128–140. PMID 24360800. DOI: 10.1016/j.clinthera.2013.11.006.
Peng Wen Pao, Keng Boon Wee, Woon Chee Yee and Zacharias Aloysius DwiPramono (April 2014). Dual Masking of Specific Negative Splicing Regulatory Elements Resulted in Maximal Exon 7 Inclusion of SMN2 Gene. Molecular Therapy 22: 854–861. PMID 24317636. PMC 3982506. DOI: 10.1038/mt.2013.276. The sequence of nusinersen (UCACUUUCAUAAUGCUGG) is listed as N1-Hua in Table I.
Garber, K (11 October 2016). Big win possible for Ionis/Biogen antisense drug in muscular atrophy.. Nature Biotechnology 34 (10): 1002–1003. PMID 27727217. DOI: 10.1038/nbt1016-1002.

nytimes.com

Katie Thomas, "Costly Drug for Fatal Muscular Disease Wins F.D.A. Approval", New York Times, 30 december 2016.

reuters.com

(en) "Biogen's pricey muscle drug Spinraza too costly for Britain", Reuters, 13 augustus 2018. Geraadpleegd op 28 mei 2019.

sciencemag.org

Wadman, Meredith (23 december 2016). Updated: FDA approves drug that rescues babies with fatal neurodegenerative disease. Science.

sma-schweiz.ch

(de) Spinraza – Zulassung nun auch in der Schweiz. SMA Schweiz (30 september 2017).

springer.com

adisinsight.springer.com

Nusinersen. AdisInsight. Geraadpleegd op 1 January 2017.

the-scientist.com

Offord, Catherine, "Oligonucleotide Therapeutics Near Approval", The Scientist, 1 december 2016.

thepharmaletter.com

Biogen to launch Spinraza in Japan soon (10 juli 2017).

treatsma.uk

(en) Spinraza access by country. TreatSMA. Geraadpleegd op 28 mei 2019.

web.archive.org

Nusinersen. UK Specialist Pharmacy Service. Gearchiveerd op 13 april 2019. Geraadpleegd op 31 december 2016.
Tarr, Peter, "CSHL FDA approval of life-saving SMA drug is hailed by its researcher-inventor at CSHL", Cold Spring Harbor Laboratory, 24 december 2016. Gearchiveerd op 1 januari 2017. Geraadpleegd op 8 maart 2020.
Therapeutic Approaches. www.curesma.org. Cure SMA. Gearchiveerd op 1 januari 2017. Geraadpleegd op 1 January 2017.
"Press release: Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy | Biogen Media", Biogen, August 1, 2016. Gearchiveerd op 10 augustus 2017. Geraadpleegd op 8 maart 2020.
Regulatory Applications for SMA Therapy Nusinersen Accepted in US, EU. BioNews Services, LLC. Gearchiveerd op 15 augustus 2020. Geraadpleegd op 15 november 2016.
Spinraza (nusinersen). European Medicines Agency. Gearchiveerd op 28 oktober 2017. Geraadpleegd op 27 oktober 2017.
"Biogen's SPINRAZA™ (nusinersen) Receives Notice of Compliance from Health Canada for the Treatment of 5q Spinal Muscular Atrophy (SMA)", Cision, 4 juli 2017. Gearchiveerd op 4 december 2017. Geraadpleegd op 8 maart 2020.
"Biogen statement on Expanded Access Programme", Muscular Dystrophy UK, 2 december 2018. Gearchiveerd op 28 februari 2019. Geraadpleegd op 27 February 2019.
NICE recommends first ever treatment for children with rare muscle-wasting condition. National Institute of Health and Care Excellence (15 May 2019). Gearchiveerd op 28 mei 2019. Geraadpleegd op 28 mei 2019.

who.int

International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 74 413–414. World Health Organization. Geraadpleegd op 13 March 2017.

worldcat.org

(en) Ottesen, Eric W. (1 januari 2017). ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy. Translational Neuroscience 8 (1): 1–6. ISSN: 2081-6936. PMID 28400976. PMC 5382937. DOI: 10.1515/tnsci-2017-0001.
(en) (1 augustus 2018). New warning of nusinersen-related communicating hydrocephalus. Reactions Weekly 1714 (1): 3. ISSN: 1179-2051. DOI: 10.1007/s40278-018-50183-2.

wsj.com

Grant, Charley, Surprise Drug Approval Is Holiday Gift for Biogen (27 december 2016). Geraadpleegd op 27 december 2016.